ETFIQData as of Nov 19, 2026. · etfiq.com/funds/bbh

BBH Fact Sheet: VanEck Biotech ETF

Share
$239.49
close, Nov 20, 2026

Over the year to Nov 19, 2026, BBH returned +28.4% in total and charged 0.35% a year.

1-year total return
+27.1%
to Nov 20, 2026
Expense ratio
0.35%
a year
Net assets
$509m
on Nov 19, 2026

Growth of $10,000, 1 year

BBH $12,842 +28.4% · ACWI $10,902 +9.0% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−4.4%
3 months−0.7%
Year to date+26.5%
1 year+27.1%
3 years+62.5%
5 years+26.9%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
Amgen Inc16.42%
Gilead Sciences Inc14.80%
Vertex Pharmaceuticals Inc8.23%
Regeneron Pharmaceuticals Inc7.95%
Moderna Inc6.31%
Argenx Se4.53%
Iqvia Holdings Inc4.18%
Natera Inc3.77%
Revolution Medicines Inc3.29%
Beone Medicines Ltd3.03%

BBH top ten by weight, 72.5% of the fund, of its 25 equity positions, from the holdings published by its issuer for Nov 19, 2026.

Facts

Holds 25 stocks in biotech, 65% of its weight in S&P 500 companies · First traded Dec 20, 2011 · Benchmark Its own holdings, as of Nov 18, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, BBH Fact Sheet: VanEck Biotech ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/bbh/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/bbh.